The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Evaluation of patient reporting of adverse drug reactions to the UK ‘Yellow Card Scheme’: literature review, descriptive and qualitative analyses, and questionnaire surveys
Open accessAbstract
BACKGROUND: The monitoring of adverse drug reactions (ADRs) through pharmacovigilance is vital to patient safety. Spontaneous reporting of ADRs is one method of pharmacovigilance, and in the UK this is undertaken through the Yellow Card Scheme (YCS). Yellow Card reports are submitted to the Medicines and Healthcare products Regulatory Agency (MHRA) by post, telephone or via the internet. The MHRA electronically records and reviews information submitted so that important safety issues can be detected. While previous studies have shown differences between patient and health-care professional (HCP) reports for the types of drugs and reactions reported, relatively little is known about the pharmacovigilance impact of patient reports. There have also been few studies on the views and experiences of patients/consumers on the reporting of suspected ADRs. OBJECTIVES: To evaluate the pharmacovigilance impact of patient reporting of ADRs by analysing reports of suspected ADRs from the UK YCS and comparing reports from patients and HCPs. To elicit the views and experiences of patients and the public about patient reporting of ADRs. DESIGN: (1) Literature review and survey of international experiences of consumer reporting of ADRs; (2) descriptive analysis of Yellow Card reports; (3) signal generation analysis of Yellow Card reports; (4) qualitative analysis of Yellow Card reports; (5) questionnaire survey of patients reporting on Yellow Cards; (6) qualitative analysis of telephone interviews with patient reporters to the scheme; (7) qualitative analysis of focus groups and usability testing of the patient YCS; and (8) national omnibus telephone survey of public awareness of the YCS. PARTICIPANTS: Patients (n = 5180) and HCPs (n = 20,949) submitting Yellow Card reports from October 2005 to September 2007. Respondents to questionnaire survey (n = 1362). Participants at focus groups and usability testing sessions (n = 40). National omnibus telephone survey (n = 2028). SETTING: The literature review included studies in English from across the world. All other components included populations from the UK; the omnibus survey was restricted to Great Britain. INTERVENTIONS: None. MAIN OUTCOME MEASURES: Characteristics of patient reports: types of drug and suspected ADR reported; seriousness of reports; and content of reports. The relative contributions of patient reports and of HCP reports to signal generation. Views and experiences of patient reporters. Views of members of the public about the YCS, including user-friendliness and usability of different ways of patient reporting. Public awareness of the YCS. Suggestions for improving patient reporting to the YCS. RESULTS: Compared with HCPs, patient reports to the YCS contained a higher median number of suspected ADRs per report, and described reactions in more detail. The proportions of reports categorised as 'serious' were similar; the patterns of drugs and reactions reported differed. Patient reports were richer in their descriptions of reactions than those from HCPs, and more often noted the effects of ADRs on patients' lives. Combining patient and HCP reports generated more potential signals than HCP reports alone; some potential signals in the 'HCP-only' data set were lost when combined with patient reports, but fewer than those gained; the addition of patient reports to HCP reports identified 47 new 'serious' reactions not previously included in 'Summaries of Product Characteristics'. Most patient reporters found it fairly easy to make reports, although improvements to the scheme were suggested, including greater publicity and the redesign of web- and paper-based reporting systems. Among members of the public, 8.5% were aware of the YCS in 2009. CONCLUSIONS: Patient reporting of suspected ADRs has the potential to add value to pharmacovigilance by reporting types of drugs and reactions different from those reported by HCPs; generating new potential signals; and describing suspected ADRs in enough detail to provide useful information on likely causality and impact on patients' lives. These findings suggest that further promotion of patient reporting to the YCS is justified, along with improvements to existing reporting systems. In order of priority, future work should include further investigation of (1) the pharmacovigilance impact of patient reporting in a longer-term study; (2) the optimum approach to signal generation analysis of patient and HCP reports; (3) the burden of ADRs in terms of impact on patients' lives; (4) the knowledge and attitudes of HCPs towards patient reporting of ADRs; (5) the value of using patient reports of ADRs to help other patients and HCPs who are seeking information on patient experiences of ADRs; and (6) the impact of increasing publicity and/or enhancements to reporting systems on the numbers and types of Yellow Card reports from patients. FUNDING: The National Institute for Health Research Health Technology Assessment programme.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A method for estimating the probability of adverse drug reactions
Naranjo, C. A., Busto, U., Sellers, E. M., Sandor, P., Ruiz, I., Roberts, E. A., Janecek, E., Domecq, C., & Greenblatt, D. J. (1981) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1981.154 · Cited by 11,914
Sampling for qualitative research
Marshall, M. N. (1996) · Family Practice · doi:10.1093/fampra/13.6.522 · Cited by 4,293
Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients
Pirmohamed, M., James, S., Meakin, S., Green, C., Scott, A. K., Walley, T. J., Farrar, K., Park, B. K., & Breckenridge, A. M. (2004) · BMJ · doi:10.1136/bmj.329.7456.15 · Cited by 3,230
(1958) · Journal of the American Pharmaceutical Association (Scientific ed.) · doi:10.1002/jps.3030470133 · Cited by 2,489
Under-Reporting of Adverse Drug Reactions: A Systematic Review
Hazell, L., & Shakir, S. A. W. (2006) · Drug Safety · doi:10.2165/00002018-200629050-00003 · Cited by 1,931
Self-citationEvans, S. J. W., Waller, P. C., & Davis, S. (2001) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.677 · Cited by 1,802
Adverse Drug Events in Ambulatory Care
Gandhi, T. K., Weingart, S. N., Borus, J., Seger, A. C., Peterson, J., Burdick, E., Seger, D. L., Shu, K., Federico, F., Leape, L. L., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmsa020703 · Cited by 1,345
Quantitative signal detection using spontaneous ADR reporting
Bate, A., & Evans, S. J. W. (2009) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1742 · Cited by 912
Dumouchel, W. (1999) · The American Statistician · doi:10.1080/00031305.1999.10474456 · Cited by 878
Patient care information systems and health care work: a sociotechnical approach
Berg, M. (1999) · International Journal of Medical Informatics · doi:10.1016/s1386-5056(99)00011-8 · Cited by 786
Adverse Drug Reactions in Hospital In-Patients: A Prospective Analysis of 3695 Patient-Episodes
Davies, E. C., Green, C. F., Taylor, S., Williamson, P. R., Mottram, D. R., & Pirmohamed, M. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004439 · Cited by 692
The Missing Voice of Patients in Drug-Safety Reporting
Basch, E. (2010) · New England Journal of Medicine · doi:10.1056/nejmp0911494 · Cited by 646
British National Formulary: BNF
(2015) · doi:10.18578/bnf_147942626 · Cited by 641
Fromme, E. K., Eilers, K. M., Mori, M., Hsieh, Y.-C., & Beer, T. M. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.03.025 · Cited by 555
Adverse drug events in hospitalized patients
van den Bemt, P. M. L. A., Egberts, A. C. G., Lenderink, A. W., Verzijl, J. M., Simons, K. A., van der Pol, W. S. C. J. M., & Leufkens, H. G. M. (1999) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050611 · Cited by 460
Thomas, K., & Coleman, P. (2004) · Journal of Public Health · doi:10.1093/pubmed/fdh139 · Cited by 303
Blenkinsopp, A., Wilkie, P., Wang, M., & Routledge, P. A. (2007) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2006.02746.x · Cited by 302
Płusa, T. (2012) · Journal of Health Policy & Outcomes Research · doi:10.7365/jhpor.2012.1.1 · Cited by 298
Women encounter ADRs more often than do men
Zopf, Y., Rabe, C., Neubert, A., Gaßmann, K. G., Rascher, W., Hahn, E. G., Brune, K., & Dormann, H. (2008) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-008-0494-6 · Cited by 200
Adverse Drug Reaction Reporting by Patients in the Netherlands: Three Years of Experience
de Langen, J., van Hunsel, F., Passier, A., de Jong-van den Berg, L., & van Grootheest, K. (2008) · Drug Safety · doi:10.2165/00002018-200831060-00006 · Cited by 177
Hauben, M., & Aronson, J. K. (2009) · Drug Safety · doi:10.2165/00002018-200932020-00003 · Cited by 170
Physician Response to Patient Reports of Adverse Drug Effects
Golomb, B. A., McGraw, J. J., Evans, M. A., & Dimsdale, J. E. (2007) · Drug Safety · doi:10.2165/00002018-200730080-00003 · Cited by 131
Egberts, T. C. G., Smulders, M., Koning, F. H. P. D., et al. (1996) · BMJ · doi:10.1136/bmj.313.7056.530 · Cited by 117
Consumer Reporting of Adverse Drug Reactions
Aagaard, L., Nielsen, L. H., & Hansen, E. H. (2009) · Drug Safety · doi:10.2165/11316680-000000000-00000 · Cited by 113
Adverse Drug Reaction Reporting in the UK
McLernon, D. J., Bond, C. M., Hannaford, P. C., Watson, M. C., Lee, A. J., Hazell, L., & Avery, A. J. (2010) · Drug Safety · doi:10.2165/11536510-000000000-00000 · Cited by 105
Self-citationReporting of adverse drug reactions by hospital doctors and the response to intervention
McGettigan, P., Golden, J., Conroy, R. M., et al. (1997) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1997.00616.x · Cited by 96
Influence of the pharmaceutical industry
Schofield, T. (1983) · BMJ · doi:10.1136/bmj.287.6407.1802-a · Cited by 86
Medawar, C., & Herxheimer, A. (2004) · International Journal of Risk & Safety in Medicine · Cited by 80
Bardage, D. I. C. (2000) · Blood Pressure · doi:10.1080/080370500300000905 · Cited by 70
Ståhl, M., Lindquist, M., Edwards, I. R., et al. (2004) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.894 · Cited by 60
Making the Most of Spontaneous Adverse Drug Reaction Reporting
WALLER, P. C. (2006) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2006.pto_286.x · Cited by 58
van Geffen, E. C. V., van der Wal, S., van Hulten, R. V., de Groot, M. D., Egberts, A. C. G., & Heerdink, E. (2007) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-007-0375-4 · Cited by 55
Perry, B. A., & Turner, L. W. (2001) · Journal of Women & Aging · doi:10.1300/j074v13n04_04 · Cited by 42
Reporting Adverse Drug Reactions
Wooten, J. M. (2009) · Southern Medical Journal · doi:10.1097/smj.0b013e318194bc67 · Cited by 36
What Can Consumer Adverse Drug Reaction Reporting Add to Existing Health Professional-Based Systems?
Fernandopulle, R., & Weerasuriya, K. (2003) · Drug Safety · doi:10.2165/00002018-200326040-00002 · Cited by 35
Patient reporting of adverse drug reactions: useful information for pain management?
Jarernsiripornkul, N., Krska, J., Richards, R. M. E., & Capps, P. (2003) · European Journal of Pain · doi:10.1016/s1090-3801(02)00114-3 · Cited by 34
Self-citationA Model for Decision Support in Signal Triage
Levitan, B. S., Yee, C. L., Russo, L., et al. (2008) · Drug Safety · doi:10.2165/00002018-200831090-00001 · Cited by 23
Foster, J. M., van der Molen, T., & van den Berg, L. D. J. (2007) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-007-0339-8 · Cited by 18
Statistical methods for knowledge discovery in adverse drug reaction surveillance.
Norén, G. N. (2007) · KTH Publication Database DiVA (KTH Royal Institute of Technology) · Cited by 10
Cited by
Onakpoya, I. J., Heneghan, C. J., & Aronson, J. K. (2016) · BMC Medicine · doi:10.1186/s12916-016-0553-2 · Cited by 616
Nikfarjam, A., Sarker, A., O’Connor, K., Ginn, R., & Gonzalez, G. (2015) · Journal of the American Medical Informatics Association · doi:10.1093/jamia/ocu041 · Cited by 543
Coleman, J. J., & Pontefract, S. K. (2016) · Clinical Medicine · doi:10.7861/clinmedicine.16-5-481 · Cited by 399
Implementing TIMERS: the race against hard-to-heal wounds
Atkin, L., Bućko, Z., Montero, E. C., Cutting, K., Moffatt, C., Probst, A., Romanelli, M., Schultz, G. S., & Tettelbach, W. (2019) · Journal of Wound Care · doi:10.12968/jowc.2019.28.sup3a.s1 · Cited by 369
The value of patient reporting to the pharmacovigilance system: a systematic review
Inácio, P., Cavaco, A., & Airaksinen, M. (2017) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13098 · Cited by 269
Metadata
- Authors
- Avery, A., Anderson, C., Bond, C., Fortnum, H., Gifford, A., Hannaford, P., Hazell, L., Krska, J., Lee, A., McLernon, D., Murphy, E., Shakir, S., & Watson, M.
- Venue
- Health Technology Assessment
- Published
- 2011-05
- Volume
- 15
- Issue
- 20
- Pages
- 1-234, iii
- ISSN
- 1366-5278 (ISSN-L)
- 2046-4924
- OpenAlex
- W1979812611
- Cited by
- 331
- References
- 39
- FWCI
- 27.86
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.